Appointment Changes at Cincinnati Children’s

We have stopped scheduling new visits to CCED during this national health emergency. If you are interested in being seen by our center when scheduling re-opens, contact us at cced@cchmc.org.

Regular follow-up appointments for established patients who are stable are being reviewed and rescheduled. Most scopes are being rescheduled. You will be contacted if these changes affect your child. If you have questions for your clinical team, contact them via MyChart.

Info on Eosinophilic Diseases and COVID-19

  • Eosinophilic Gastrointestinal Diseases (EGID) are not immunodeficiency disorders.
  • The medical literature does not support a concerning association between eosinophil-associated diseases and coronaviruses.  
  • There is no known increased risk for viral infections in patients with EGID. 
  • Patients on eosinophil-depleting drugs, such as benralizumab, mepolizumab, and reslizumab, as well as patients on dupilumab, have not been reported to have an increased risk of viral infections and / or complications from viral infections.
  • Patients with eosinophilia have not been reported to have an increased risk of viral infections.
  • Eosinophils are not the primary cells involved in protective immunity against viruses.
  • Topical glucocorticoids (fluticasone and budesonide) are not systemically immunosuppressive, unlike prednisone, which is systemically immunosuppressive.
  • A caveat to this information concerns rare EGID and other eosinophilic syndromes that may have other underlying disease components, such as immunosuppression induced by systemic steroids such as prednisone; these patients may have increased risk for complications. Such patients should consult with their primary doctor for specific advice and guidance. 
  • It is important to emphasize that we do not have substantial data to demonstrate that there is increased risk of harm with COVID-19 when EGID or hypereosinophilic syndromes are present.

Research Participants

  • Patients in research studies should make personal decisions about the risk / reward of continuing to participate and adhere to local and national health department guidelines regarding travel and preparedness.
  • Subjects with concurrent viral-like illnesses should reschedule their study visits.
  • If you have specific questions regarding your trial related to the known risks of the COVID-19 virus, contact your specific research trial team.